Follow us on Twitter
twitter icon@FreshPatents

Expression Vector patents

      

This page is updated frequently with new Expression Vector-related patent applications.




 Cell expression system patent thumbnailnew patent Cell expression system
An expression system for expressing a protein comprising: a eukaryotic host cell carrying a dihydrofolate reductase (dhfr) deficiency; and an expression vector, the expression vector encoding the human growth hormone gene; a expression vector, the expression vector comprising: a eukaryotic selectable marker including a minimal sv 40 early promoter driving expression of a sequence encoding dihydrofolate reductase for complementing the dhfr deficiency in the host cell; a prokaryotic selectable marker conveying ampicillin resistance to a prokaryotic host cell; a prokaryotic origin of replication; a plurality of multiple cloning sites (mcs); and at least one protein expression module comprising: a simian vacuolating virus 40 (sv40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit β-globin intron sequence being separable from a sv40 p a sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom.. .
Neuclone Biologics Pty Ltd


 Novel ferulate esterase isolated from lactobaccillus fermentum patent thumbnailnew patent Novel ferulate esterase isolated from lactobaccillus fermentum
The cdna and amino acid sequences of a ferulate esterase obtained from lactobacillus fermentum nrrl b-1932 is determined. An expression vector for expression of the ferulate esterase gene is generated.
The United States Of America, As Represented By The Secretary Of Agriculture


 Use of endostatin peptides for the treatment of fibrosis patent thumbnailnew patent Use of endostatin peptides for the treatment of fibrosis
C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


 Novel epitope for switching to th17 cell and use thereof patent thumbnailnew patent Novel epitope for switching to th17 cell and use thereof
The present invention relates to a novel epitope to convert t cell to type 17 helper t (th17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (seq id no.
National Cancer Center


 Puma protein expression vector and use thereof in gene therapy patent thumbnailnew patent Puma protein expression vector and use thereof in gene therapy
The present invention relates to a viral vector for expression of the cell death-inducing puma protein, for use in gene therapy, for example for the treatment of rheumatoid arthritis. This vector consists in particular of a recombinant adenovirus expressing the gene encoding the puma protein and of a recombinant baculovirus containing a coxsackie-adenovirus receptor (car)..
Institut National De La Sante Et De La Recherche Medicale (inserm)


 Dual vector for inhibition of human immunodeficiency virus patent thumbnailnew patent Dual vector for inhibition of human immunodeficiency virus
The present invention provides an expression vector for preventing or inhibiting hiv entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a hiv co-receptor, such as ccr5 or cxcr4, and a protein that inhibits hiv fusion to target cells and/or hiv replication.
Calimmune, Inc.


 Non-ribosomal protein synthesis pigment fusion peptides patent thumbnailNon-ribosomal protein synthesis pigment fusion peptides
The present invention relates to a polypeptide or polypeptide complex, comprising at least one non-ribosomal peptide synthesis (nrps) amino acid module functionally connected to at least one pigment module. The present invention further relates to a labeled oligopeptide comprising a non-naturally attached nrps pigment or/and polyketide pigment, to a polynucleotide encoding a fusion polypeptide, a vector, preferably an expression vector, comprising the polynucleotide of the present invention and to a host cell comprising the polypeptide or polypeptide complex and/or the polynucleotide, and/or the vector according to the present invention.
Ruprecht-karls-universität Heidelberg


 Non-silencing selectable marker genes and methods of use patent thumbnailNon-silencing selectable marker genes and methods of use
Provided are nucleic acids and expression vectors having a non-silencing selectable marker gene, and methods of using the same. A subject expression vector includes an expression cassette and a non-silencing selectable marker gene.
The Board Of Trustees Of The Leland Stanford Junior University


 Methods and compositions of human recombinant growth and differentiaton factor-5 (rhgdf-5) isolated from inclusion bodies patent thumbnailMethods and compositions of human recombinant growth and differentiaton factor-5 (rhgdf-5) isolated from inclusion bodies
expression vector systems are provided for increased production of a recombinant gdf-5 (rhgdf-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhgdf-5 protein.
Warsaw Orthopedic, Inc.


 Formulations of 5-fluorocytosine and uses thereof patent thumbnailFormulations of 5-fluorocytosine and uses thereof
The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided.
Tocagen Inc.


Process for generating synthetic engineered recombinant proteins for vaccination, diagnosis and treatment of disease


A process for generating a synthetic engineered recombinant protein has been performed by providing an original protein design and the necessary probabilistic priors for random in silico assembly. Once the in silico synthetic protein is assayed using mathematic modeling, the proteins are then reverse translated into dna.

Polynucleotide encoding acyl-coa synthetase homolog and use thereof


The present invention relates to an acyl-coa synthetase homolog protein from microorganisms of the genus mortierella, a polynucleotide encoding the protein, and so on. The invention provides polynucleotides comprising an acyl-coa synthetase homolog protein gene from, e.g., mortierella alpina, expression vectors comprising these polynucleotides and transformants thereof, a method for producing lipids or fatty acids using the transformants, food products containing the lipids or fatty acids produced by the method, etc..
Suntory Holdings Limited


Polynucleotide encoding acyl-coa synthetase homolog and use thereof


The present invention relates to an acyl-coa synthetase homolog protein from microorganisms of the genus mortierella, a polynucleotide encoding the protein, and so on. The invention provides polynucleotides comprising an acyl-coa synthetase homolog protein gene from, e.g., mortierella alpina, expression vectors comprising these polynucleotides and transformants thereof, a method for producing lipids or fatty acids using the transformants, food products containing the lipids or fatty acids produced by the method, etc..
Suntory Holdings Limited


Enzyme-catalyzed enantioselective aziridination of olefins


The present invention provides methods for catalyzing the conversion of an olefin to a compound containing one or more aziridine functional groups using heme enzymes. In certain aspects, the present invention provides a reaction mixture for producing an aziridination product, the reaction mixture comprising of an olefinic substrate, a nitrene precursor, and a heme enzyme.
California Institute Of Technology


Generation of ips cells and associated methods


Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating ips cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter..
University Of Utah Research Foundation


Expression active goldfish tgf2 transposon recombinant transposase protein


An expression method of active goldfish gftp1 transposase protein comprises: constructing an expression vector comprising a gftp1 transposase reading frame of a goldfish tgf2 transposon, after transferred into escherichia coli rosetta 1(de3), culturing an expression strain until absorbance of a bacteria solution under od600 reaches 0.3-0.4, adding iptg, culturing under 21-22° c. In shaking of 150-200 rpm, inducing to express soluble recombinant protein, and purifying to obtain a functionally active transposase.
Shanghai Ocean University


Method for mass production of factor vii/viia derivatives


A method for mass production of human coagulation factor vii derivatives. The method employs an expression vector, containing i) a nucleotide sequence of dhfr promoter devoid of at least one ccgccc repeat sequence from the gc-rich region thereof and a nucleotide sequence encoding a dhfr operably linked thereto, and ii) a nucleotide sequence of cmv early gene promoter and a nucleotide sequence encoding a human coagulation factor vii derivative operably linked thereto; and adds at least one selected from the group consisting of sodium butyrate, vitamin k, and a culture medium supplement..
Hanmi Pharm. Co., Ltd.


Water-soluble expression and purification human gcsf recombinant protein having biological activities


The present invention relates to a water-soluble expression and a purification method of a human granulocyte colony-stimulating factor (hgcsf) recombinant protein having biological activities using an n-terminal tag, and provides a recombinant expression vector containing a solubility enhancing tag and a hgcsf gene. In addition, provided are: a recombinant microorganism transformed with the recombinant expression vector; a method for producing a hgcsf recombinant protein (rhgcsf); and a rhgcsf produced by the production method..
University Of Ulsan Foundation For Industry Cooperation


Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays


Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein.
Monogram Biosciences, Inc.


Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides


Herein is reported that for transient transfections the use of the human elongation factor 1 alpha promoter (with intron a) provides for an enhanced productivity (in lc-hc-sm organization), the use of the bovine growth hormone polya signal sequence provides for an enhanced productivity compared to use of the sv40 polya signal sequence, the addition of the hgt to the bgh polya signal sequence results in an increased productivity in vectors containing the hcmv promoter and the vector organization lc(3′-5′)-hc-sm results in improved expression. For stable pools it is reported that pools generated with vectors containing the hef1α promoter show an enhanced productivity in batch analysis, clones generated with vectors containing the hef1α promoter show a reduced number of low producing clones, and clones generated with vectors containing the hef1α promoter show a higher stability of igg expression.
Hoffmann-la Roche Inc.


Expression vector production and high-throughput cell screening


The present invention relates inter alia to expression vector production as well as application to the production of host cells for protein repertoire expression and high-throughput screening. The invention also relates to primers useful for pcr amplification of nucleotide sequences encoding human antibody variable domains..
Kymab Limited


Human monoclonal antibodies specific for glypican-3 and use thereof


Described herein is the identification of human monoclonal antibodies that bind gpc3 or heparan sulfate (hs) chains on gpc3 with high affinity. The antibodies described herein are capable of inhibiting hcc cell growth and migration.
The U.s.a., As Represented By The Secretary, Department Of Health And Human Services


Antibodies to endoplasmin and their use


Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human.
University Of Pittsburgh - Of The Commonwealth Sys Tem Of Higher Education


Arabidopsis nonhost resistance gene(s) and use thereof to engineer sds resistant plants


The present invention relates to a method of increasing resistance against plant pathogens, particularly fusarium virguliforme and phytophthora sojae in transgenic plants and/or plant cells, through the use of non host resistance nucleic acid molecules isolated from arabidopsis. In these plants, at least one nonhost arabidopsis resistance protein is introduced in comparison to the wild-type plants to confer resistance to plant pathogens.
Iowa State University Research Foundation, Inc.


Endo-xylanase and coding gene and use thereof


Provided are an endo-xylanase and a coding gene and the use thereof. Also provided are an expression vector and a host cell containing the coding gene, a method for forming a simple sugar by using the xylanase, a xylanase mutant with an improved thermal stability and a method for improving the thermal stability of the xylanase..
Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences


Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof


The invention provides antibodies that specifically bind to plasminogen activator inhibitor type-1 (pai-1), the invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-pai-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate pai-1 activity or detect pai-1, either in vitro or in vivo, are also provided.
Sanofi


Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer


The invention provides chimeric antigen receptors (cars) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain t cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Exogenous gene expression vector, transformant discrimination marker, and transformant


This invention is intended to develop a promoter that can strongly induce marker gene expression throughout an embryo, so as to simply, efficiently, and accurately identify a transgenic insect at an early developmental stage, and to provide a gene expression vector into which such promoter has been incorporated as a transformant discrimination marker. Such exogenous gene expression vector comprises a polynucleotide comprising the nucleotide sequence as shown in seq id no: 1 as a promoter..
National Institute Of Agrobiological Sciences


Expression vectors for recombinant protein production in mammalian cells


The invention provides expression vectors that support high levels of polypeptide expression in mammalian cells. The vectors contain at least one expression cassette for a target polypeptide; an expression cassette for a eukaryotic selectable marker protein; an expression cassette for a bacterial selectable marker protein, and a bacterial plasmid origin of replication..
Merck Sharp & Dohme Corp.


Glycine max resistance gene(s) and use thereof to engineer plants with broad-spectrum resistance to fungal pathogens and pests


The present invention relates to a method of increasing plant resistance to plant pathogens, particularly sudden death syndrome in soybean against fusarium virguliforme, through the use of fusarium resistance nucleic acid molecules isolated from glycine max and fusarium virguliforme. In these plants, at least one heterologous fusarium resistance protein is introduced in comparison to the wild-type plants to confer resistance to plant pathogens.
Iowa State University Research Foundation, Inc.


Expression vector


An expression vector including two separately inducible converging promoters p1 and p2, and expression system including such an expression vector and an additional regulator vector, a method of protein expression using such an expression system, and a method of investigating (meta)genome libraries using such an expression system.. .
C-lecta Gmbh


Feline bitter taste receptors and methods


A family of novel feline bitter taste receptors, referred to as feline tas2r (ftas2r), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors.

Optimized expression cassette for expressing a polypeptide with high yield


The present invention is based on the finding that the combination of a specific 5′utr polynucleotide sequence (see seq id no 1) and the hcd33 secretory leader sequence in an expression cassette for expressing a polypeptide of interest results in a surprisingly better expression level of the polypeptide of interest compared to prior art expression cassettes. Based on this finding, the present invention inter alia provides novel expression cassettes, expression vectors and methods for producing a polypeptide of interest with high yield..

Insecticidal proteins and methods for their use


Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.

Expression vector for production of recombinant proteins in prokaryotic host cells


An expression vector for production of a recombinant protein in a host cell is provided. The expression vector includes a nucleotide sequence of sequence id no 2 encoding for a leader peptide of sequence id no 3..

Cell and gene based methods to improve cardiac function


Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit r1-encoding nucleic acid sequence and a ribonucleotide reductase subunit r2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium.

Immune system mediator


The present invention discloses an isolated nucleic acid molecule encoding an israa polypeptide comprising at least 70% homology to the sequence represented by the nucleotide sequence seq id no: 1. Also disclosed is a recombinant expression vector comprising said nucleic acid molecule and an isolated polypeptide molecule encoded by said nucleic acid molecule..

Recombinant protein expression using a hybrid chef1 promoter


The invention provides expression vectors and host cells for high-level expression of recombinant proteins. The expression vectors comprise chinese hamster ovary elongation factor 1-α (chef1) transcriptional regulatory dna elements and a cytomegalovirus (cmv) promoter and/or a human adenovirus tripartite leader (adtpl) sequence.

Random rna libraries, methods of generating same, and screening methods utilizing same


This invention provides sets and libraries of short hairpin ribonucleic acid (shrna) molecules comprising a double-stranded region of random sequence containing random mismatches, methods of generating same, sets and libraries of expression vectors for same, methods of generating same, and methods for identifying an rna therapeutic or rna molecule that has an ability to affect a biological parameter, for identifying a drug target for a disease or disorder of interest, and for identifying a variant of an rna molecule that has an altered ability to affect a biological parameter of interest.. .

Method for producing alpha-santalene


The present invention provides a method of producing α-santalene by contacting at least one polypeptide with farnesyl phyrophosphate (fpp). In particular, the method may be carried out in vitro or in vivo to produce α-santalene, a very useful compound in the fields of perfumery and flavoring.

Antibodies to tigit


The present invention provides antibodies, or antigen binding fragments thereof, that bind to human tigit (t cell immunoreceptor with ig and itim domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the pd-1/pd-l1 interaction.

Expression vector for cyanobacteria


The present disclosure discloses a vector that can be used for both cyanobacteria and e. Coli, which contains, sequentially, a puc replication origin as a replication origin; a spectinomycin-resistant gene as a selection marker; and a promoter selected from a group consisting of a trc promoter, a teta promoter or a modified teta promoter, a bad promoter and a cbbl promoter.
Korea Institute Of Science And Technology


Antibodies directed to her-3 and uses thereof


The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Amgen, Inc.


Human monoclonal antibodies to o8e


The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to o8e with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L.l.c.


Process for production of insulin and insulin analogues


A process for production of insulin or insulin analogues by expression of insulin or insulin analogues through an expression vector in a host cell is provided. The expression vector includes a leader peptide of seq id no 3; a nucleotide sequence encoding an affinity tag linked to c-terminal end or n terminal end of nucleotide sequence of the leader peptide; and a nucleotide sequence encoding for a cleavage site ligated to nucleotide sequence of the leader peptide through nucleotide sequence encoding the affinity tag..
Biogenomics Limited


Plants expressing cell wall degrading enzymes and expression vectors


Vectors for expression of proteins in plants are described. The proteins may be enzymes and the enzymes can be but are not limited to cell wall degrading enzymes.
Agrivida, Inc.


Methods of producing two chain proteins in bacteria


Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes..
Genentech, Inc.


Methods of producing two chain proteins in bacteria


Provided herein are methods of producing a recombinant polypeptide containing two chains, such as an immune mobilizing monoclonal t-cell receptor against cancer (immtac) protein including an alpha chain and a beta chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes..
Genentech, Inc.


Bgl6 beta-glucosidase and nucleic acids encoding the same


The present invention provides a novel β-glucosidase nucleic acid sequence, designated bgl6, and the corresponding bgl6 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding bgl6, recombinant bgl6 proteins and methods for producing the same..
Danisco Us Inc.


Biosensors that detect nad+


A polypeptide biosensor that detects free nad+ is disclosed. The polypeptide comprises a first fragment from an nad+ dependent dna ligase acetylation domain, a second fragment from the nad+ dependent dna ligase acetylation domain, and a fluorescent protein, wherein the fluorescent protein is positioned between the two dna ligase acetylation domain fragments.
Oregon Health & Science University


Antibodies directed to ricin toxin


An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to ricin toxin, an expression vector including the isolated nucleic acid molecule and a host cell transfected with said isolated nucleic acid molecule or with the expression vector, a pharmaceutical composition including as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule or the immunoconjugate and a pharmaceutically acceptable carrier, excipient or diluent, and a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule, the immunoconjugate or the pharmaceutical composition.. .
The Israel Institute Of Biological Research (iibr)


Anti-human papillomavirus 16 e6 t cell receptors


Disclosed is a t cell receptor (tcr) having antigenic specificity for an hla-a2-restricted epitope of human papillomavirus (hpv) 16 e6, e629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Stepwise differentiation of stem cells for the production of eukaryotic membrane proteins


A method useful for making a eukaryotic membrane protein in vitro may be carried out by (a) propagating in vitro vertebrate stem cells; (b) transforming the vertebrate stem cells in vitro with a heterologous expression vector containing a nucleic acid encoding the eukaryotic membrane protein; and then (c) differentiating the stem cells in vitro into differentiated cells (or photoreceptor-like cells) that express the membrane protein.. .
Uab Research Foundation


An integrated system for library construction, affinity binder screening and expression thereof


A recombinant polynucleotide suitable for use in a display vector is provided. The recombinant polynucleotide includes from 5′ to 3′: a first nucleic acid sequence (or insert) encoding an amino acid sequence to be displayed on a surface; a first pre-selected restriction site; a second nucleic acid sequence encoding a surface peptide capable of being displayed on the surface; and a second pre-selected restriction site.
Adagene Inc.


Subtilase variants and polynucleotides encoding same


The present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance. The variants of the invention are suitable for use in e.g.
Novozymes A/s


Subtilase variants and polynucleotides encoding same


The present invention relates to novel subtilase variants exhibiting increased stability and optionally on par or improved wash performance. The variants of the invention are suitable for use in e.g.
Novozymes A/s


Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor


Disclosed is a protein comprising a cytolethal distending toxin subunit b (cdtb) conjugated or fused to a bacillus anthracis toxin lethal factor (lf) or a functional portion of lf. Related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of inhibiting the growth of a target cell are also disclosed..
Department Of Health And Human Services


Antibodies against cd73 and uses thereof


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human cluster of differentiation 73 (cd73) with high affinity, and inhibit the activity of cd73, and optionally mediate antibody dependent cd73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Bristol-myers Squibb Company


Human monoclonal antibodies specific for cd22


Disclosed herein are isolated human monoclonal antibodies that specifically bind human cd22 with a dissociation constant (kd) of 25 nm or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of


Subtilase variants and polynucleotides encoding same


The present invention relates to novel subtilase variants exhibiting increased stability and optionally on par or improved wash performance. The variants of the invention are suitable for use in e.g.
Novozymes A/s


Novel cytochrome p450 enzymes from sorghum bicolor


Two novel cytochrome p450 genes are isolated from sorghum, each gene encoding a protein having pentadecatrienyl resorcinol hydroxylase activity. Expression vectors containing these sequences are made and used to elevate levels of pentadecatrienyl resorcinol hydroxylase in transgenic cells and organisms..
The United States Of America, As Represented By The Secretary Of Agriculture


Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (jev) and their use


Disclosed herein are isolated humanized monoclonal antibodies that specifically bind japanese encephalitis virus (jev) with a binding affinity of about 1.0 nm or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


Method for refining protein including self-cutting cassette and use thereof


The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by lpxtg, a domain of sortase a having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method..
Scripps Korea Antibody Institute


Cosmetic composition for improving skin conditions comprising fusion protein


The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein.
Lg Household & Health Care Ltd.


Glycoengineered antibody drug conjugates


The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation


Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation


Methods for preventing or inhibiting inflammation in a subject are disclosed. In one aspect, the method comprises administering to a subject diagnosed with an inflammatory disease an effective amount of an anti-inflammatory agent that (1) inhibits the expression of cxcl9, cxcl10, cxcl11, cxcl13, cxcr3 and/or cxcr5, or (2) inhibits the interaction between cxcr3 and cxcl9, cxcl10 or cxcl11, or between cxcr5 and cxcl13, or (3) inhibits a biological activity of cxcl9, cxcl10, cxcl11, cxcl13, cxcr3 and/or cxcr5, wherein the agent comprises an antibody, antibody fragment, short interfering rna (sirna), aptamer, synbody, binding agent, peptide, aptamer-sirna chimera, single stranded antisense oligonucleotide, triplex forming oligonucleotide, ribozyme, external guide sequence, or an agent-encoding expression vector..
Jyant Technologies, Inc.


Antibodies to human signal peptide-containing proteins


The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


Stress tolerant plants and methods thereof


The present invention provides a method and dna molecules that when expressed in a plant produces transgenic plants with improved abiotic stress tolerance. The invention includes plant expression vectors comprising the dna molecules, and plants containing such dna molecules..
Monsanto Technology Llc


Novel molecules of the card-related protein family and uses thereof


Novel card-9, card-10, or card-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated card-9, card-10, or card-11 proteins, the invention further provides card-9, card-10, or card-11, fusion proteins, antigenic peptides and anti-card-9, card-10, or card-11 antibodies.
Millennium Pharmaceuticals, Inc.


Recombinant baculovirus expression vector and cell


A recombinant baculovirus expression vector or cell comprising an engineered baculovirus fp25k gene with one to three modified or mutated spots, the modified spots comprise the two 7-adenine mononucleotide repeats (mnr) and the 10th ttaa site. The invention also provides the method of making the vector and baculovirus..
Miami University


Method for producing antibody using "naked" expression vector expressing type ii transmembrane fusion protein


Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) cd134l, a fragment, homologous or orthologues protein thereof as n-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as c-terminal moiety of the fusion protein.
Delphi Genetics Sa


Retro polypeptides for activation immunity to cancer and viral infection


A polypeptide that drives t cell proliferation and differentiation, and methods and agents for modulating the expression and/or function of the polypeptide. Agents that up regulate the expression and/or function of the polypeptide are useful in the treatment or prevention of diseases and disorders that would benefit from stimulation of t cell proliferation and/or differentiation, such as cancer and chronic viral infections.
Imperial Innovations Limited


Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use


Isolated vhh monoclonal antibodies are disclosed that specifically bind to a norovirus polypeptide. In some embodiments, the norovirus is a genogroup i norovirus or a genogroup ii norovirus.

Mutant factor viii compositions and methods


In one aspect, present invention provides a recombinant mutant human factor viii having increased expression and/or secretion as compared to wild-type factor viii. In certain embodiments, the recombinant factor viii includes one or more amino acid substitution(s) selected from the group consisting of i86, y105, a108, d115, q117, f129, g132, h134, m147 and l152.

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

Expression systems and associated methods


A method of producing synthetic spider silk, including: transforming escherichia coli with an expression vector; fermenting the transformed e. Coli in a culture medium; inducing spider silk protein expression in the cultured e.

Yeast promoters from pichia pastoris


In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences


Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

Therapeutic agent for neurological disorder


Provided is a therapeutic agent for a neurological disorder directly acting on oxygen concentration-dependent vascular barrier breakdown. The therapeutic agent for a neurological disorder contains any one of (a) a functional nucleic acid against adam (a disintegrin and metalloproteinase)12 or adam17, (b) a functional nucleic acid expression vector containing a dna encoding the functional nucleic acid (a) and (c) a neutralizing antibody against adam12 or adam17, as an active ingredient.
Yamaguchi University


Methods and compositions for inducing protective immunity against human immunodeficiency virus infection


Compositions, vaccines and methods for inducing protective immunity against human immunodeficiency virus (hiv) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of hiv..
Crucell Holland B.v.


Expression process


A process for the production of a target polypeptide is provided. The process comprises expression of an expression vector for expressing a target polypeptide in a host cell, preferably a mammalian cell, the expression vector comprising an expression cassette comprising a polynucleotide encoding a recombinant polypeptide operably linked to a fibronectin secretion leader sequence; and recovering the target polypeptide..
Fujifilm Diosynth Biotechnologies Uk Limited


Anti-vasa antibodies, and methods of production and use thereof


Anti-vasa antibodies (mabs), particularly humanized mabs that specifically bind to vasa with high affinity, are disclosed. The amino acid sequences of the cdrs of the light chains and the heavy chains, as well as consensus sequences for these cdrs, of these anti-vasa mabs are provided.
Ovascience, Inc.


Human monoclonal antibodies to programmed death ligand 1 (pd-l1)


The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L. L. C.


Fungal resistant plants expressing mybtf


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales in plants and/or plant cells. This is achieved by increasing the expression of a mybtf protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy


Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell.
Alderbio Holdings Llc


Positive-selection cloning and expression vector based on the toxicity of killin


Here we report the creation of a new positive-selection cloning vector dubbed pkillin, which overcomes all of the above pitfalls. The essence behind its high cloning efficiency is the extreme toxicity and small size of the toxic domain of killin, a recently discovered p53 target gene.

Site-specific glycoengineering of targeting moieties


The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation


Immunotherapy of cancer through combination of local and systemic immune stimulation


Provided herein are compositions and methods for immunotherapy of cancers, said methods combining systemic vaccination with a recombinant expression vector encoding a viral antigen and/or a cancer specific tumor antigen(s) to induce activated cd8 t-cells, with a local (e.g., intratumoral) immune stimulation using standard or modified application of a tlr agonist, to induce local inflammatory and innate immune responses which recruit t-cells to the tumor.. .
Immune Design Corp.


Anti-cd276 polypeptides, proteins, and chimeric antigen receptors


Polypeptides and proteins that specifically bind to and immunologically recognize cd276 are disclosed. Chimeric antigen receptors (cars), anti-cd276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed.
Biomed Valley Discoveries, Inc.


Neisserial antigenic peptides


This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria neisseria meningitidis b. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids).
Glaxosmithkline Biologicals Sa


Production of fully processed and functional factor x in a furin-secreting mammalian expression system


Disclosed herein are methods for production of fully-processed mature factor x in an expression system producing a controlled amount of furin between 50 u/ml and 300 u/ml of culture supernatant. Also disclosed are transformed cells, expression systems, and expression vectors for the expression of furin and factor x..
Baxalta Gmbh


Enzymatic methods and enzymes


Provided are methods to identify modulators and in particular inhibitors of body malodour formation employing peptidase enzymes, the peptidase enzymes and corresponding nucleotide sequences, expression vectors, transfected host cells, methods of forming the peptidase enzymes and methods to prevent body malodour.. .
Givaudan Sa


Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy


The present invention is based, in part, on our discovery that targeting epitopes within one or more of the ec2-ec5 subdomains of e-cadherin results in the death of epithelial-derived tumor cells but not in the death of normal, healthy epithelial cells or non-epithelial cells including endothelial cells and fibroblasts. Accordingly, the compositions of the invention include polypeptides having an amino acid sequence of one or more of the ec2-ec5 subdomains of e-cadherin and biologically active variants thereof; expression vectors and cells for expressing such polypeptides; and agents (e.g., antibodies) that target the ec2-ec5 subdomains.
The Research Foundation For The State University Of New York


Methods and constructs for expressing biologically active proteins in mammalian cells


Methods and constructs for expressing biologically active proteins in eukaryotic cells are disclosed. A method for producing a non-conventional expression vector for production of biologically active compounds comprising a primary transcriptional unit and one or more secondary transcriptional units, a primary transcriptional unit encoding promoter, synthetic intron, selectable marker gene and polyadenylation signal or transcriptional terminator and a second transcriptional unit encoding promoter and polypeptide of interest surrounded by insulator sequences and placed in the intron of primary transcriptional unit.
Usha Biotech Limited


Novel epitope for switching to th2 cell and use thereof


The present invention relates to a novel epitope to convert t cell to type 2 helper t (th2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody..

Pseudomonas exotoxin a with less immunogenic b cell epitopes


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more of amino acid residues e420, d463, y481, l516, r563, d581, d589, and k606, wherein the amino acid residues are defined by reference to seq id no: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Expression vector and preparing a polypeptide of interest using the same


A fusion polynucleotide including a human cmv promoter and an intron, a recombinant vector including the fusion polynucleotide and a gene encoding a polypeptide of interest, a recombinant cell comprising the recombinant vector, and a method of producing a polypeptide of interest using the recombinant vector or recombinant cell.. .
Samsung Electronics Co., Ltd.


Phi-4 polypeptides and methods for their use


Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
Pioneer Hi-bred International, Inc.


Fungal resistant plants expressing hcp5


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an hcp5 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


Light-switchable gene expression system and the methods for controlling gene expression in prokaryotic bacterium


Provided is an optically controlled gene expression system of prokaryotic bacterium, comprising: a) a photosensitive recombinant transcription factor encoding gene, the photosensitive recombinant transcription factor is one fusion protein comprising a first polypeptide as the dna bonding domain and a second polypeptide as the photosensitive domain; b) a target transcription unit comprising promoter or promoter-reaction element or reaction element-promoter containing at least one reaction element recognized/bound by the first polypeptide and the nucleic acid sequence to be transcribed. Also provided is a prokaryotic expression vector comprising said optically controlled gene expression system, and a method for regulating gene expression in a prokaryotic host cell by using the optically controlled gene expression system.
East China University Of Science And Technology


Multi-chain eukaryotic display vectors and uses thereof


A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin fab fragments.
Dyax Corp.




Expression Vector topics:
  • Expression Vector
  • Recombinant
  • Nucleic Acid
  • Antibodies
  • Polypeptide
  • Amino Acid
  • Amino Acid Sequence
  • Nucleic Acids
  • Polynucleotide
  • Nucleotide
  • Cytomegalovirus
  • Endothelial
  • Extracellular
  • Endothelial Cell
  • Epithelial


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.8886

    5574

    469599 - 0 - 105